These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 22721367)

  • 41. A benefit-risk assessment of baclofen in severe spinal spasticity.
    Dario A; Tomei G
    Drug Saf; 2004; 27(11):799-818. PubMed ID: 15350152
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Comparative effectiveness of different muscle relaxants in the rehabilitation of post-stroke patients with spasticity].
    Lipták J
    Ideggyogy Sz; 2013 Nov; 66(11-12):429. PubMed ID: 24555245
    [No Abstract]   [Full Text] [Related]  

  • 43. Functional effects of spinal baclofen.
    Müller H
    Przegl Lek; 2007; 64 Suppl 2():1-2. PubMed ID: 17953269
    [No Abstract]   [Full Text] [Related]  

  • 44. Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study.
    Latino P; Castelli L; Prosperini L; Marchetti MR; Pozzilli C; Giovannelli M
    Neurol Sci; 2017 Oct; 38(10):1841-1848. PubMed ID: 28766025
    [TBL] [Abstract][Full Text] [Related]  

  • 45. THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
    Trojano M
    Eur Neurol; 2016; 75 Suppl 1():4-8. PubMed ID: 26901343
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury.
    Kamen L; Henney HR; Runyan JD
    Curr Med Res Opin; 2008 Feb; 24(2):425-39. PubMed ID: 18167175
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity.
    Bensmail D; Quera Salva MA; Roche N; Benyahia S; Bohic M; Denys P; Bussel B; Lofaso F
    Neurology; 2006 Oct; 67(8):1432-6. PubMed ID: 17060570
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Continuous intrathecal infusion of baclofen. A new therapeutic method for spasticity].
    Berg-Johnsen J; Røste GK; Solgaard T; Lundar T
    Tidsskr Nor Laegeforen; 1998 Sep; 118(21):3256-60. PubMed ID: 9772811
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up.
    Rekand T; Grønning M
    J Rehabil Med; 2011 May; 43(6):511-4. PubMed ID: 21533331
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potentiation of botulinum toxin type A with oral anti-spasticity medications in the management of focal spasticity.
    Dai A
    J Rehabil Med; 2007 Mar; 39(2):189; author reply 189. PubMed ID: 17351705
    [No Abstract]   [Full Text] [Related]  

  • 51. Treatment of spasticity in a spinal cord-injured patient with intrathecal morphine due to intrathecal baclofen tolerance--a case report and review of literature.
    Soni BM; Mani RM; Oo T; Vaidyanathan S
    Spinal Cord; 2003 Oct; 41(10):586-9. PubMed ID: 14504619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of spasticity.
    Rösche J
    Spinal Cord; 2002 Jun; 40(6):261-2. PubMed ID: 12037705
    [No Abstract]   [Full Text] [Related]  

  • 53. Preventative treatment for migraine and tension-type headaches : do drugs having effects on muscle spasm and tone have a role?
    Freitag FG
    CNS Drugs; 2003; 17(6):373-81. PubMed ID: 12696998
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study.
    Simpson DM; Gracies JM; Yablon SA; Barbano R; Brashear A;
    J Neurol Neurosurg Psychiatry; 2009 Apr; 80(4):380-5. PubMed ID: 18977811
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adherence associated with oral medications in the treatment of spasticity.
    Halpern R; Gillard P; Graham GD; Varon SF; Zorowitz RD
    PM R; 2013 Sep; 5(9):747-56. PubMed ID: 23648652
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review.
    Taricco M; Pagliacci MC; Telaro E; Adone R
    Eura Medicophys; 2006 Mar; 42(1):5-15. PubMed ID: 16565680
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution.
    Draulans N; Vermeersch K; Degraeuwe B; Meurrens T; Peers K; Nuttin B; Kiekens C
    Clin Rehabil; 2013 Dec; 27(12):1137-43. PubMed ID: 23858524
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity.
    Ward A; Roberts G; Warner J; Gillard S
    J Rehabil Med; 2005 Jul; 37(4):252-7. PubMed ID: 16024483
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients.
    Hoogstraten MC; van der Ploeg RJ; vd Burg W; Vreeling A; van Marle S; Minderhoud JM
    Acta Neurol Scand; 1988 Mar; 77(3):224-30. PubMed ID: 3376747
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The pharmacological management of spasticity.
    Saulino M; Jacobs BW
    J Neurosci Nurs; 2006 Dec; 38(6):456-9. PubMed ID: 17233517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.